214870 — NewGLab Pharma Co Balance Sheet
0.000.00%
Last trade - 00:00
TechnologySpeculativeMicro Cap
R2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Interim Report | Annual Audited Accounts | ARS | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 43,266 | 44,171 | 43,467 | 11,039 | 4,524 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 27,509 | 41,911 | 14,715 | 4,005 | 13,165 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 89,999 | 99,785 | 78,367 | 21,955 | 19,077 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 5,391 | 5,248 | 7,412 | 6,594 | 2,318 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 117,184 | 127,028 | 113,779 | 29,946 | 30,239 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 46,184 | 58,042 | 78,581 | 49,734 | 50,267 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 51,321 | 63,723 | 84,858 | 49,369 | 47,733 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
ESOP Debt Guarantee | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 65,863 | 63,305 | 28,920 | -19,424 | -17,495 |
Total Liabilities & Shareholders' Equity | 117,184 | 127,028 | 113,779 | 29,946 | 30,239 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |